BRCA1 and ovarian cancer: FANCM mutation testing in women with HGSOC might also have clinical utility through targeted treatment with Poly (ADP-ribose) polymerase (PARP) inhibitors, which are currently being evaluated in women with BRCA1 and BRCA2 associated ovarian cancer.